COMMON STOCK PURCHASE WARRANT LIXTE BIOTECHNOLOGY HOLDINGS, INC.Common Stock Purchase Warrant • November 27th, 2020 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [ ] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the initial exercise date first set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on November 30 2025 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Lixte Biotechnology Holdings, Inc., a Delaware corporation (the “Company”), up to ______ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant shall initially be issued and maintained in the form of a security held in book-entry form and the Depository Trust Company or its nominee (“DTC”) shall initially be the sole registered holder of
LIXTE BIOTECHNOLOGY HOLDINGS, INC. UNDERWRITING AGREEMENT 1,200,000 Units Consisting of 1,200,000 Shares of Common Stock And 1,200,000 Warrants to Purchase 1,200,000 Shares of Common StockUnderwriting Agreement • November 27th, 2020 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
LIXTE BIOTECHNOLOGY HOLDINGS, INC., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell to the underwriters named in Schedule I hereto (the “Underwriters,” or each, an “Underwriter”), for whom WestPark Capital Inc. and WallachBeth Capital, LLC are acting as representatives (the “Representatives”), an aggregate of 1,200,000 Units (the “Firm Units”), each Firm Unit consisting of one share of the Company’s common stock, $0.001 par value per share (the “Common Stock”) and one warrant to purchase one share of Common Stock (the “Warrants” and each a “Warrant”). The 1,200,000 shares of Common Stock referred to in this Section are hereinafter referred to as the “Firm Shares” and the Warrants referred to in this Section are hereinafter referred to as the “Firm Warrants,” and together with the Firm Units and the Firm Shares, the “Firm Securities.” The Firm Warrants shall be issued pursuant to, and shall have the rights and privil
WARRANT AGENT AGREEMENTWarrant Agent Agreement • November 27th, 2020 • Lixte Biotechnology Holdings, Inc. • Pharmaceutical preparations • New York
This Warrant Agent Agreement (“Warrant Agreement”) is made as of November 30, 2020, by and between Lixte Biotechnology Holdings, Inc., a Delaware corporation, with offices at 248 Route 25A, No.22 East Setauket, NY 11733 (the “Company”), and Computershare Inc., a Delaware corporation, and its wholly-owned subsidiary Computershare Trust Company N.A. a federally chartered trust company (collectively, the “Warrant Agent”).
